Keywords: fda, panel, says, darvon, risks, outweigh, benefits

FDA panel says Darvon risks outweigh benefits

Article | 23 February 2009

Print This

The analgesics Darvon (propoxyphene) and Darvocet (propoxyphene and acetaminophen), both from US drug major Eli Lilly, should be taken off ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in